HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in Am J Health-Syst Pharm Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dobesh, P. P. Search for Related Content PubMed PubMed Citation Articles by Dobesh, P. P.

PAUL P. DOBESH, PHARM.D., FCCP, BCPS, is Associate Professor, Department of Pharmacy Practice, College of Pharmacy, Room 4045, 986045 University of Nebraska Medical Center, Omaha, NE 68198-6045 (pdobesh{at}unmc.edu).

Purpose. Current guideline recommendations for effective strategies to optimize the treatment of patients with concomitant hypertension and type 2 diabetes mellitus are reviewed. Summary. Current estimates indicate that 20 million people in the United States have diabetes, 90–95% of whom have type 2 diabetes mellitus. Type 2 diabetes mellitus is associated with an increased risk of premature death from cardiovascular disease (CVD), stroke, and end-stage renal disease. Hypertension is an extremely common comorbidity in patients with type 2 diabetes mellitus. The coexistence of hypertension in patients with type 2 diabetes is particularly destructive because of the strong linkage of the two conditions with CVD, stroke, progression of renal disease, and diabetic nephropathy. Current guidelines, including those issued by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National Kidney Foundation, and the American Diabetes Association, provide evidence-based recommendations for the treatment of hypertension in patients with type 2 diabetes mellitus. However, studies indicate that guidelines are not widely followed. Therefore, the beneficial effects of appropriate hypertension treatment observed in clinical trials are often not recognized in clinical practice. Pharmacists are ideally positioned to help improve guideline implementation and patient outcome. Conclusion. Pharmacists must become more vigilant about following current guidelines for the treatment of patients with concomitant hypertension and type 2 diabetes mellitus. Strategies such as patient education and medication assessment can help to optimize care for these patients and slow the progression to diabetic nephropathy. Index terms: Diabetes mellitus; Drug use; Hypertension; Hypotensive agents; Patient information; Pharmacists; Protocols; Rational therapy

 

Related articles in Am J Health-Syst Pharm:

Role of the pharmacist in managing hypertension in patients with diabetes

James E. Tisdale
Am J Health-Syst Pharm 2006 63: 1129. [Full Text]  

This article has been cited by other articles:

				H. J. Zhao, S. Wang, H. Cheng, M.-z. Zhang, T. Takahashi, A. B. Fogo, M. D. Breyer, and R. C. Harris Endothelial Nitric Oxide Synthase Deficiency Produces Accelerated Nephropathy in Diabetic Mice J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2664 - 2669. [Abstract] [Full Text] [PDF]

				J. E. Tisdale Role of the pharmacist in managing hypertension in patients with diabetes. Am. J. Health Syst. Pharm., June 15, 2006; 63(12): 1129 - 1129. [Full Text] [PDF]